Kornimate/medical-research-clean huggingface dataset:
dlaag in the treatment of acute myeloid leukemia (aml) and myelodysplastic syndrome with blast excess

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome

Summary: the purpose of this study is to evaluate of the clinical efficacy and safety of dlaag protocol in the treatment of acute myeloid leukemia (aml) and myelodysplastic syndrome with blast excess


Eligibility criteria:
inclusion criteria: 1. corresponding to the aml (except m3) or high-risk mds diagnostic criteria, with any of the following circumstances: ①secondary aml patients (including aml secondary to mds) ②corresponding to refractory aml diagnostic standard ( relapsed refractory acute myeloid leukemia chinese guidelines(2017 edition): refractory aml diagnostic criteria: invalid after standard treatment 2 cycles of untreated cases; consolidation therapy after cr and then recurrence within 12 months; recurrence after 12 months and then invalid after conventional chemotherapy ; relapse of ≥ 2 times ; extramedullary leukemia continued existence. ③corresponding to recurrent aml diagnostic criteria (relapsed refractory acute myeloid leukemia china guidelines (2017 edition): peripheral blood leukemia cells or bone marrow progenitor cells appear again \> 0.050 after cr (with the exception of bone marrow regeneration after consolidation chemotherapy and other reasons) or leukemia cells infiltration appear in extramedullary ④corresponding to mds refractory anemia with blasts excess (raeb) diagnosis standards 2. age ≥18 years old 3. eastern cooperative oncology group(ecog) score 0-3 4. expected survival ≥8 weeks 5. patients must be able to understand and be willing to participate in this study, and signed informed consent exclusion criteria: 1. acute promyelocytic leukemia (m3 type) 2. other types of mds patients except raeb 3. with other advanced malignant tumors 4. patients with uncontrolled severe infection, and can not tolerate chemotherapy with other serious underlying diseases 5. patients with heart failure: ejection fraction (ef) \< 30%, new york heart association(nyha) standard, cardiac insufficiency in class ii or above

Keywords: decitabine retinoid acid cytarabine c granulocyte colony stimulating factor acute myeloid leukemia myelodysplastic syndrome
does using a low vision aid device improve quality of life in glaucoma patients?

Conditions: Glaucoma

Summary: to determine the impact of orcam over 1 month on health-related quality of life (hrqol) in subjects with advanced glaucoma using the national eye institute visual function questionnaire 25 (nei-vfq-25). to identify tasks for which subjects are using the orcam device and patient satisfaction.

participants will document their daily impression about the use of orcam, a small camera attached to their glasses over a 1-month period. they will attend 2 appointments at wills eye hospital glaucoma research center (baseline and final visit). participant's will be trained to use the orcam device at baseline visit and complete a best-corrected visual acuity assessment etdrs (early treatment diabetic retinopathy study) and the nei-vfq-25 questionnaire. they will also read a short newspaper article. the nei-vfq-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. items within each subscale are averaged together to create 12 subscale scores. an overall composite score will be calculated by averaging vision-targeted subscale scores, excluding the general health rating question. participants will read a short article. they will be asked to grade their reading difficulty between 1 (unable to read) to 10 (able to read without difficulty). time to read article will be recorded. reading task will be performed with best correction - with and without the assistance of the orcam device. subjects will utilize orcam daily for one month. each week, subjects will record thoughts about the device in a log book or by using audio tape recorder, according to patient's personal preference. final assessment at 1 month will include best-corrected visual acuity (etdrs), nei-vfq-25, and the newspaper-reading task with and without orcam assistance. a satisfaction questionnaire will be completed in order to assess subjects' overall feelings regarding orcam. audio log books will be analyzed for specific factors and recorded by a research assistant.

Eligibility criteria:
inclusion criteria: * glaucoma any type, characterized by glaucomatous optic neuropathy and corresponding visual field (vf) defect * visual acuity of 20/400 to hand motion (hm) in better eye or visual field less than 10 degrees in better eye and having difficulty reading. * age 18 years or older * able to understand and speak english * able to use an electronic recording device * able to operate a computerized system exclusion criteria: * neurological or musculoskeletal problems that would influence performance on activities of daily living * incisional eye surgery within past three months * laser therapy within previous month * any cause for visual impairment other than glaucoma * photophobia * any medical condition precluding subject from providing reliable, valid data

Keywords: orcam low-vision device end-stage glaucoma
laser therapy for at-home treatment of diabetic foot ulcers - canada

Conditions: Diabetic Foot Ulcer

Summary: the global prevalence of diabetes is on the rise and with it increase in prevalence of diabetic foot ulcers (dfu). these recalcitrant wounds are difficult to manage and pose a heavy economic burden. photobiomodulation (low level laser) is used for acceleration of wound healing. the current study is designed to evaluate the effectiveness of b-cure laser, a home-use low-level laser device, for acceleration of diabetic foot ulcer healing over standard treatment.

patients with diabetic foot ulcers will receive standard treatment and in addition will be randomly allocated to receive either active or sham laser device to self treat at home. the patient's wound will be evaluated every 2 weeks. adverse events will be documented. the study hypothesis is that b-cure laser treatments as an adjunct therapy to standard treatment, applied, at home, by the patient or personal care-giver, can accelerate diabetic foot ulcers healing compared to standard treatment alone.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female 4. age:18-95 years old at the time of informed consent (adult, senior) 5. type 1 or type 2 diabetes mellitus 6. presence of a diabetic foot ulcer located in the ankle area or below that has persisted a minimum of 3 months prior to the screening visit 7. ulcer grade classified as ≥2 according to wagner grading system. 8. area of ulcer (after debridement) is at least 2 cm2 9. arterial perfusion: patients who demonstrate adequate arterial perfusion defined as either: ankle/brachial index (abi) above 0.5 or that have documented confirmation of adequate arterial perfusion 10. patient and/or caregiver must be able and willing to learn and perform the duties of dressing changes 11. for females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation exclusion criteria: 1. pre-existing conditions - active malignancy, 2. anemia (hb\<8 gr/dl) 3. scheduled to undergo vascular surgery, angioplasty, or thrombolysis at the time of enrollment. 4. history of malignancy on study limb or currently receiving or has received radiation or chemotherapy within 3 months of randomization 5. taking immunosuppressive medication 6. received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of screening 7. hba1c \> 12% (uncontrolled hyperglycemia) 8. a documented history of alcohol or substance abuse within 6 months of screening 9. currently enrolled or who have participated, within 30 days of screening, in another investigational device, drug or biological trial that may interfere with study results 10. pregnant at the time of screening 11. has any photobiomodulation (low level laser) device at home

Keywords: photobiomodulation low-level laser therapy over the counter
study of brain response to emotional pictures using a fmri while on duloxetine

Conditions: Major Depression

Summary: the purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients. the genetic samples collected are to look at variation in a gene (serotonin transporter gene), which affects the functioning of the chemical serotonin in the brain

this study will measure the activity in different parts of the brain, while the patients are seeing some pictures, using magnetic resonance imaging (mri) scan. for this study three mri scans will be conducted. one before the patient begins on any medication, one during the study after 3 weeks of treatment and one after six more weeks of treatment with a standard antidepressant called duloxetine.

Eligibility criteria:
inclusion criteria for depressed patients: * ages 18 - 60 years and able to give voluntary informed consent. * satisfy criteria for major depressive disorder (mdd) and current depressed episode using the structured clinical interview for dsm-iv (scid-iv). * 17-item hamilton depression rating scale (hdrs) score \> 18. * satisfy criteria to undergo an mri scan based on mri screening questionnaire. * able to be managed as outpatients for initial assessment and during treatment as ascertained by the following: * symptoms not worsening by more than 10 points on the hdrs during the course of the study. * no danger to self or others. exclusion criteria for patients: * meeting dsm-iv criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar disorder, atypical psychosis, mental retardation, or organic mental (including organic mood) disorder. * known hypersensitivity to duloxetine or any of the inactive ingredients. * on monoamine oxidase inhibitors in the past 2 weeks. * history of narrow angle glaucoma * lack of response of the current episode of depression to two or more adequate courses of antidepressant therapy at a clinically appropriate dose for a minimum of 4 weeks or, in the judgment of the investigator, the patient meets criteria for treatment-resistant depression. * use of neuroleptic in the past 2 weeks. * use of antidepressants in the past 2 weeks. if on fluoxetine in the past, then should not have been on this medication for 4 weeks. * history of lack of response to duloxetine. * use of mood stabilizers in the past 2 weeks. * use of benzodiazepines in the past 2 weeks. * acutely suicidal or homicidal or requiring inpatient treatment. * meeting dsm-iv criteria for other substance dependence within the past year, except caffeine or nicotine. the criteria will be evaluated by interview and urinary toxicology screening initially and on test days. * use of alcohol in the past 1 week. * no serious medical or neurological illness as assessed by physical examination and laboratory examination including cbc and blood chemistry. * current pregnancy or breast-feeding. * metallic implants. * previously known positive hiv blood test as reported by the subject.

Keywords: depression duloxetine fmri pictures
achieving conduction system activation with leadless left ventricular endocardial pacing

Conditions: Heart Failure

Summary: the goal of this prospective non-randomised study is to test the feasibility of leadless conduction system pacing using the wise-crt device in patients with an indication for cardiac resynchronisation therapy. the main question\[s\] it aims to answer are: 1. what is the safety profile of leadless conduction system pacing? 2. what is the success rate of leadless conduction system pacing? 3. what are the electrical and haemodynamic effects of leadless conduction system pacing. participants will undergo pre-procedural cardiac ct, and post-procedure electro-anatomical mapping and haemodynamic assessments.


Eligibility criteria:
inclusion criteria: * age over 18 years * ability to provide informed consent to participate and willing to comply with the clinical investigation plan and follow-up schedule. * patients meeting european society of cardiology criteria for cardiac resynchronization therapy (crt) with class 1 or 2a recommendation: * dyssynchronous heart failure: left ventricular ejection fraction (lvef) ≤35%, qrs duration \>150ms or \>130ms in presence of left bundle branch block (lbbb). also included here are patients with ef ≤35%, an existing pacing system and an rv pacing burden of \>20%. * block hf population: patients requiring pacing for atrioventricular (av) block with an lvef ≤50% * av node ablation (avna) population: patients planned for avna with ef ≤50%. exclusion criteria: * any contraindication to lv endocardial pacing. * lv thrombus * contra-indication to heparin * contra-indication to anti-platelet agents * failure of acoustic window screening * septal wall thickness \<5mm (minimum required wall thickness at any target implant site) * myocardial infarction within 40 days prior to enrolment. * cardiac surgery or coronary revascularisation procedure within 3 months prior to enrolment or to be scheduled for such procedures within the following 7 months. * participation in other studies with active treatment/investigational arm. * pregnant or planning to become pregnant in the next 7 months.

Keywords: heart failure cardiac resynchronisation therapy leadless pacing
efficacy and safety study of tacrobell to treat rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the aims of this study are to assess the efficacy and safety of tacrolimus in patients with active rheumatoid arthritis(ra). eular(european league against rheumatism) response at week 24 compared to baseline will be evaluated to assess the efficacy of tacrolimus.

a phase iv, open labeled, multi-center trial to assess the efficacy and safety of tacrolimus(tacrobell®)in patients with active rheumatoid arthritis(ra).

Eligibility criteria:
inclusion criteria: * male or female aged ≥20years * signed and dated informed consent document indicating that the patient * women of childbearing potential must have a negative serum or urine pregnancy test at the screening visit. except in the case of surgically sterile or amenorrhea for one year. * female patients must agree to use adequate contraception measures during the period of therapy which should be continued for 4 weeks. * have ra and meet all of the following criteria; ra occurring ≥ 3months and less than 15 years and diagnosed based on 1987 acr classification criteria for rheumatoid arthritis; active ra patients with mtx and among them who has insufficiency response to dmards as defined das28\>3.2 in active ra patient. insufficiency response is defined despite mtx therapy for \> 12 weeks, ra activity≥ more than moderate and confirmable during 12 weeks, sequence of taking mtx \>7.5mg/week for more than 6 weeks; esr≥28mm/h or crp≥1.0mg/dl; tender joint counts must be more than 6 and swollen joint counts must be more than 3 exclusion criteria: * inflammatory joint diseases, systematic inflammatory disease * prosthesis and had an event of infected in it. * medical history of chronic infection, moderate infection or possibly to life threatening or signs and symptoms of serious infection. * patients have received treatment with a live vaccine from baseline within 8 weeks. * hbsag positive and hepatitis c virus positive patient. * patients have a history of malignancy. (but, carcinoma in situ of the uterine cervix or basal cell carcinoma have been treated is allowed within 5years) * patients have cardiovascular disease or associated disease which is not controlled. * uncontrollable blood sugar(hba1c ≥8%) or required insulin. * patients with a history of operation on index knee joint which could have influence on the result and need to have surgery as determined by investigator. * at screening, patients have laboratory result as defined by ; white blood cell(wbc) \ 1.5\*upper limit of normal or 2mg/dl, total bilirubin \> 2\*upper limit of normal, aspartate aminotransferase(ast) \> 2\*upper limit of normal, alanine aminotransferase(alt) \> 2\*upper limit of normal, alkaline phosphatase(alp) \> 2\*upper limit of normal * patients on any other clinical trial or experimental treatment in the past 8weeks * an impossible one who participates in clinical trial by investigator's decision

Keywords: rheumatoid arthritis ra tacrolimus disease activity score 28 eular
does tranexamic acid improve visualization during arthroscopic rotator cuff repair

Conditions: Rotator Cuff Tears; Rotator Cuff Injuries; Subacromial Impingement; Subacromial Impingement Syndrome

Summary: this clinical trial examines whether intravenous preoperative administration of tranexamic acid (txa) before arthroscopic rotator cuff repair (arcr) can improve arthroscopic visualization during the procedure.


Eligibility criteria:
inclusion criteria: * age 18-100 * male and female * patient able to read and understand consent form * non-traumatic, simple small or medium sized rotator cuff tear as defined by pre-operative mri * booked to operating room for elective rotator cuff repair * beach chair positioning exclusion criteria: * patient refusal to participate * massive rotator cuff tear * acute traumatic rotator cuff tear * known coagulopathy * patients with a history or risk of thromboembolism * known hypersensitivity to tranexamic acid * patient unable to be off anti-coagulant medication for long enough to counter effects * patient has a clinic systolic blood pressure \> 150mmhg * lateral positioning * requirement or insistence by patient or anesthesiologist on regional block * patients who have smoked nicotine products within the last year * the presence of other inflammatory conditions (calcific tendonitis, rheumatoid arthritis, etc.) * the presence of active thromboembolic disease, such as deep vein thrombosis, pulmonary embolism, and cerebral thrombosis * patient has a seizure disorder * patients on medications identified as having drug-drug interactions (hormonal contraceptive, hydrochlorothiazide, desmopressin, sulbactam-ampicilllin, carbazochrome, ranitidine, or nitroglycerine * patient is pregnant * patients with history of subarachnoid hemorrhage * patients with renal insufficiency * patients with acquired disturbances of color vision
adolescent community reinforcement approach in combination with buprenorphine/naloxone for severe opioid use

Conditions: Opioid-Related Disorders; Behavior, Addictive

Summary: the study assesses whether adding a behavioral intervention, known as the adolescent community reinforcement approach (a-cra), to the treatment of individuals already receiving buprenorphine/naloxone can improve treatment success and retention rates in young adults with severe opioid use disorder.

buprenorphine is one of the medication assisted treatments approved by the fda for opioid use disorders. treatment with buprenorphine/naloxone may reduce the risk of opioid overdose and lower the occurrence of further conditions associated with injection drug use such as psychiatric disorders, hepatitis c infection, hiv, and high-risk sexual and criminal behaviors. the study assesses whether adding a behavioral intervention, known as the adolescent community reinforcement approach (a-cra), to the treatment of individuals already receiving buprenorphine/naloxone can improve treatment success and retention rates in young adults with severe opioid use disorder.

Eligibility criteria:
inclusion criteria: * have met dsm-5 criteria for severe opioid use disorder * no sensitivity to buprenorphine or naloxone * no further medical/addictive conditions that require immediate medical attention * ability to read and provide informed consent * intent to remain in the area for the duration of the study * able to receive outpatient care * agreed to use an acceptable birth control method throughout the duration of this study (female participants) exclusion criteria: * endorsement of imminent and serious suicidality * medical conditions that take precedence over the presence of treatment for an addictive disorder * history of an adverse reaction to buprenorphine/naloxone * current substance use or psychiatric condition requiring a level of care higher than outpatient * pregnant, nursing or planning pregnancy during the extent of the treatment trial(female participants)

Keywords: adolescent community reinforcement approach a-cra opioid-related disorders behavior psychosocial treatment pharmacotherapy randomized controlled adolescent young adult
evaluating the effectiveness of 68ga-grazytracer pet/ct in inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases (IBD)

Summary: this is a single-centre, prospective, observational cohort study in which 69 patients with inflammatory bowel disease (ibd) were recruited to undergo 68ga-grazytracer pet/ct imaging in patients with ibd to investigate the feasibility of early sensitive detection or prediction of the response to medication in patients with inflammatory bowel disease on 68ga-grazytracer pet/ct and early prediction of the the feasibility of 68ga-grazytracer pet/ct for early detection or prediction of response to drug therapy and early prediction of long-term prognosis in patients with inflammatory bowel disease.


Eligibility criteria:
inclusion criteria: * age between 18-80 years old; clinical diagnosis of inflammatory bowel disease (active stage); not having received treatment within 4 weeks prior to undergoing pet/ct examination; received endoscopy within 7 days before and after pet/ct examination; signing an informed consent form for pet/ct examination and volunteering to participate in this study. exclusion criteria: * no signed informed consent or unspecified diagnosis; female subjects are pregnant or breastfeeding and male subjects are preparing for pregnancy; those who are unfit to perform (concomitant severe and/or uncontrollable and/or unstable disease, developer allergy) or who are unable to complete imaging such as pet for specific reasons (needle-sickness, blood-sickness, claustrophobia); colitis other than inflammatory bowel disease (infectious or ischaemic colitis); patients who have undergone colon resection.

Keywords: pet/ct 68ga-grazytracer
pharmacogenetic testing in children with persistent gastroesophageal reflux disease

Conditions: Gastroesophageal Reflux

Summary: this study will use a 22 gene pharmacogenomics panel on 30 children with persistent gastroesophageal reflux disease (gerd) who have not responded to therapy.

this study will assess the clinical utility of pharmacogenomics testing in the clinical management of children with refractory gerd, despite adequate therapy and the role of pharmacogenomics in selecting the right acid suppressive therapy based on each patient's symptoms and pharmacogenomics results.

Eligibility criteria:
inclusion criteria: * persistent gastrointestinal symptoms (gi) suggestive of gastro esophageal reflux disease (gerd) despite adequate therapy * persistent evidence of abnormal reflux indices' and acid exposure on esophageal multichannel ph impedance study despite adequate therapy * persistent endoscopic evidence of reflux esophageal disease despite adequate therapy exclusion criteria: * children with eosinophilic esophagitis diagnosis * children with any esophageal surgical intervention like fundoplication, tracheoespahgeal fistula repair or esophageal atresia repair * children with other diseases that can affect the esophagus, like crohn's disease or food protein-induced enterocolitis syndrome (f-pies) * children who do not have research authorization in their chart